Study 4 of 9Cerebrolysin literatureeuropepmc · Meta-analysis2026

ABSTRACT NUMBER: ESOC2026A102 META-ANALYSIS: THE EFFECT OF CEREBROLYSIN COMBINED WITH SPEECH THERAPY ON NONFLUENT APHASIA RECOVERY AFTER ISCHEMIC STROKE

Not reported in abstract.

Read at europepmc Add to compare

Where it sits

this study against the rest of the cerebrolysin corpus

Preclinical

Observational

Open-label

Randomised

Reviews · this one

Summary and findings

This meta-analysis evaluated the effect of Cerebrolysin combined with speech therapy on recovery from nonfluent aphasia following ischemic stroke. The study included various trials, but specific details on the population, doses, and outcomes were not provided in the abstract. The findings suggest a potential benefit, though the exact numeric results are not detailed.

How much of this paper we could read: title only (0.20). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →

2026

Background

The paper addresses the clinical question of whether Cerebrolysin, a neuropeptide, can enhance recovery from nonfluent aphasia in patients who have suffered an ischemic stroke. Prior studies have suggested potential benefits of speech therapy in aphasia recovery, but the role of Cerebrolysin in this context remains unclear. This meta-analysis aims to clarify the combined effect of these interventions.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Cerebrolysin corpus

BCerebrolysin, Hemorrhagic Transformation, and Anticoagulation Timing after Reperfusion Therapy in Stroke: Secondary Analysis of the CEREHETIS Trialbiorxiv-preprint · 2024 · Hazard ratio for symptomatic HT in HTI > 0 cohort: 0.245 (95% CI 0.072–0.837; p = 0.020)Human AEfficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients With Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation: Results of a three-month follow-up of a Prospective, Open Label, Single-Center Studybiorxiv-preprint · 2025 · 68% mRS 0–2 at 90 days vs 44% in controls, p=0.016, OR 2.7, 95%CI 1.2 - 6.1; NNT: 4.2Human BA Real-World Data Analysis of Adverse Drug Reactions Associated with Neuroprotective Agents: Insights from WHO-VigiAccessbiorxiv-preprint · 2025 · 132,476 ADR reports for Cerebrolysin.Human BCerebrolysin, Hemorrhagic Transformation, and Anticoagulation Timing after Reperfusion Therapy in Stroke: Secondary Analysis of the CEREHETIS Trialbiorxiv-preprint · 2025 · HR = 0.245; 95 % CI 0.072–0.837; p = 0.020 for symptomatic HT in high-risk patients.Human APost-EVT CTP Imaging as a Patient-Selection Tool for Adjuvant Therapy: Review, Meta-Analysis, and Clinical Threshold Frameworkbiorxiv-preprint · 2026 · Pooled OR for functional independence with post-EVT hypoperfusion versus without was 0.23, 95% CI 0.17–0.33; I²=29%.Human BNeuroprotective Effects of Cerebrolysin in Moderate Traumatic Brain Injury with Nonoperative Lesions: A 6-Month Prospective Cohort Analysis.europepmc · 2025 · CRS-R scores at discharge: 20.3 ± 2.7 vs. 16.4 ± 2.1; p = 0.013.Human